The World Health Organization (WHO) has added GLP-1 drugs used for the treatment of diabetes to its Essential Medicines List. The inclusion aims to increase access to these expensive medicines.
In the catalog developed by WHO, 523 medicines for adults and 374 for children are included, which the organization believes should be available in all functioning health systems.
In the past, the inclusion of medicines in this list has helped people in low income countries gain access to life saving drugs.
The expert committee has included Ozempic and Mounjaro in the list for the treatment of type 2 diabetes.
